MedinCell Stock Value
MedinCell Company Info
EPS Growth 5Y
12,23%
Market Cap
€0,80 B
Long-Term Debt
€0,06 B
Annual earnings
06/17/2026 (E)
Dividend
€0,00
Dividend Yield
0,00%
Founded
2003
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
€32,50
47.06%
Last Update: 03/30/2026
Analysts: 8
Highest Price Target €43,00
Average Price Target €32,50
Lowest Price Target €29,20
In the last five quarters, MedinCell’s Price Target has risen from €14,82 to €22,77 - a 53,64% increase. Four analysts predict that MedinCell’s share price will increase in the coming year, reaching €32,50. This would represent an increase of 47,06%.
Top growth stocks in the health care sector (5Y.)
What does MedinCell do?
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
Business Segments
The company operates primarily in the pharmaceutical sector, focusing on the research, development, and manufacturing of innovative drug delivery systems and long-acting injectable products. The company’s business model emphasizes the creation of proprietary technology platforms that enhance therapeutic efficacy and patient compliance. This approach allows the co...
MedinCell Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Pharmaceutical sales:** 70%
**Biotechnology sales:** 20%
**Research and development services:** 10%
**TOP 3 markets:**
1. **Europe:** 45%
2. **North America:** 35%
3. **Asia-Pacific:** 15%
MedinCell S.A. generates the majority of its revenue from the pharmaceutical industry, with a...
At which locations are the company’s products manufactured?
**Production Sites:** Montpellier, France
MedinCell S.A. is a French company specializing in the development of injectable sustained-release drugs. The company's main production site is located in Montpellier, France. This is where the innovative technologies and products based on the propriet...
What strategy does MedinCell pursue for future growth?
**Strategy for Future Growth:**
1. **Focus on Innovative Drug Development:**
MedinCell S.A. is increasingly focusing on the development of innovative, long-acting injectable drugs. These are intended to improve treatment adherence and reduce treatment costs.
2. **Expansion of Partnerships:**...
Which raw materials are imported and from which countries?
**Main raw materials:** Polymers, pharmaceutical active ingredients
**Countries of origin:** USA, China, India
MedinCell S.A. mainly imports polymers and pharmaceutical active ingredients needed for the production of their innovative drug delivery systems. The polymers are primarily sourced from...
How strong is the company’s competitive advantage?
**Competitive Advantage:** Moderate to strong (estimated 2026)
MedinCell S.A. has established a solid competitive advantage through its innovative controlled drug release technology platform. This platform allows for the sustained release of medications over an extended period, increasing treatment...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** 45% (estimated, 2026)
**Insider Buys/Sells:** No significant transactions reported (2026)
The institutional investor share in MedinCell S.A. is estimated to be around 45%. This suggests that a significant number of shares are held by large financial institutions,...
What percentage market share does MedinCell have?
**Market share of MedinCell S.A.:** Estimate: 2-3% (2026)
**Major competitors and their market shares:**
1. **Johnson & Johnson:** 15%
2. **Pfizer Inc.:** 13%
3. **Roche Holding AG:** 12%
4. **Novartis AG:** 11%
5. **Sanofi S.A.:** 10%
6. **GlaxoSmithKline plc:** 9%
7. **AstraZeneca plc:** 8%
8...
Is MedinCell stock currently a good investment?
**Revenue Growth:** 18% (2025)
**Research and Development Expenses:** 35% of revenue (2025)
**Partnerships:** Collaboration with major pharmaceutical companies such as Teva Pharmaceuticals
In 2025, MedinCell S.A. achieved a revenue growth of 18%, attributed to the successful development and marke...
Does MedinCell pay a dividend – and how reliable is the payout?
**Dividend payment:** None (as of 2026)
MedinCell S.A. has not distributed any dividends to its shareholders so far. The company mainly focuses on the research and development of new drugs and technologies, which typically involves high investment costs.
In the biotechnology industry, it is not un...
